A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.

Journal Article (Journal Article)

Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.

Full Text

Duke Authors

Cited Authors

  • Muruato, AE; Fontes-Garfias, CR; Ren, P; Garcia-Blanco, MA; Menachery, VD; Xie, X; Shi, P-Y

Published Date

  • August 13, 2020

Published In

Volume / Issue

  • 11 / 1

Start / End Page

  • 4059 -

PubMed ID

  • 32792628

Pubmed Central ID

  • PMC7426916

Electronic International Standard Serial Number (EISSN)

  • 2041-1723

Digital Object Identifier (DOI)

  • 10.1038/s41467-020-17892-0


  • eng

Conference Location

  • England